Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012;8(2):121-30.
doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.

Citalopram for agitation in Alzheimer's disease: design and methods

Lea T Drye  1 , Zahinoor Ismail, Anton P Porsteinsson, Paul B Rosenberg, Daniel Weintraub, Christopher Marano, Gregory Pelton, Constantine Frangakis, Peter V Rabins, Cynthia A Munro, Curtis L Meinert, D P Devanand, Jerome Yesavage, Jacobo E Mintzer, Lon S Schneider, Bruce G Pollock, Constantine G Lyketsos; CitAD Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Citalopram for agitation in Alzheimer's disease: design and methods

Lea T Drye et al. Alzheimers Dement. 2012.

Abstract

Background: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms.

Methods: CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured.

Conclusion: The authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD.

PubMed Disclaimer

References

    1. Rabins PV, Lyketsos CG, Steele CD. Practical Dementia Care. 2nd ed. New York: Oxford University Press;
    1. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14;55(9):1271–1278. - PubMed
    1. Finkel S, Lyons J, Anderson R, Sherrell K, Davis J, Cohen-Mansfield J, Schwartz A, Gandy J, Schneider L. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int.J Geriatr.Psychiatry. 1995;10(2):129–136.
    1. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD) Int.J Geriatr.Psychiatry. 2000;15(Suppl 1):S2–S4. - PubMed
    1. Finkel SI, Costa e Silva, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 1996;8(Suppl 3):497–500. - PubMed

Publication types

MeSH terms